An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)

Axel Hauschild, Jean Jacques Grob, Lev V. Demidov, Thomas Jouary, Ralf Gutzmer, Michael Millward, Piotr Rutkowski, Christian U. Blank, Wilson H. Miller, Eckhart Kaempgen, Salvador Martin-Algarra, Boguslawa Karaszewska, Cornelia Mauch, Vanna Chiarion-Sileni, Beloo Mirakhur, Mary E. Guckert, R. Suzanne Swann, Patricia Haney, Vicki L. Goodman, Paul B. Chapman

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

27 Citations (Web of Science)
Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Issue number15
Publication statusPublished - 20 May 2013
Externally publishedYes
Event49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States
Duration: 31 May 20134 Jun 2013

Cite this